NEW YORK (GenomeWeb News) – San Diego-based Xenomics has changed its name to TrovaGene and its ticker symbol to TROV, effective yesterday.
The firm is developing molecular diagnostics based on its transrenal nucleic acid technology. TrovaGene said that it has leased a 5000-square-foot facility in the Sorrento Valley area of San Diego and is in the process of completing all the necessary laboratory validations. The firm added that it plans to expand its scientific team as it works toward becoming a fully integrated diagnostic business by the end of the second quarter of this year.
Among the products TrovaGene has in development are a KRAS assay and an assay for human papillomavirus genotypes.
TrovaGene's shares currently trade at $.59 on the Pink Sheets.